Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
- PMID: 12764551
- DOI: 10.1007/s00259-003-1194-1
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
Abstract
A high percentage of patients with mild cognitive impairment (MCI) develop clinical dementia of the Alzheimer type (AD) within 1 year. The aim of this longitudinal study was to identify characteristic patterns of cerebral metabolism at baseline in patients converting from MCI to AD, and to evaluate the changes in these patterns over time. Baseline and follow-up examinations after 1 year were performed in 22 MCI patients (12 males, 10 females, aged 69.8+/-5.8 years); these examinations included neuropsychological testing, structural cranial magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography (PET) evaluation of relative cerebral glucose metabolic rate (rCMRglc). Individual PET scans were stereotactically normalised with NEUROSTAT software (Univ. of Michigan, Ann Arbor, USA). Subsequently, statistical comparison of PET data with an age-matched healthy control population and between patient subgroups was performed using SPM 99 (Wellcome Dept. of Neuroimaging Sciences, London, UK). After 1 year, eight patients (36%) had developed probable AD (referred to as MCI(AD)), whereas 12 (55%) were still classified as having stable MCI (referred to as MCI(MCI)). Compared with the healthy control group, a reduced rCMRglc in AD-typical regions, including the temporoparietal and posterior cingulate cortex, was detected at baseline in patients with MCI(AD). Abnormalities in the posterior cingulate cortex reached significance even in comparison with the MCI(MCI) group. After 1 year, MCI(AD) patients demonstrated an additional bilateral reduction of rCMRglc in prefrontal areas, along with a further progression of the abnormalities in the parietal and posterior cingulate cortex. No such changes were observed in the MCI(MCI) group. In patients with MCI, characteristic cerebral metabolic differences can be delineated at the time of initial presentation, which helps to define prognostic subgroups. A newly emerging reduction of rCMRglc in prefrontal cortical areas is associated with the transition from MCI to AD.
Similar articles
-
Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.Psychiatry Res. 2007 Jul 15;155(2):147-54. doi: 10.1016/j.pscychresns.2006.12.003. Epub 2007 May 23. Psychiatry Res. 2007. PMID: 17524628
-
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510. doi: 10.1007/s00259-005-1762-7. Eur J Nucl Med Mol Imaging. 2005. PMID: 15747152 Review.
-
[The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].Zhonghua Yi Xue Za Zhi. 2002 Dec 10;82(23):1613-6. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12667368 Chinese.
-
A critical discussion of the role of neuroimaging in mild cognitive impairment.Acta Neurol Scand Suppl. 2003;179:52-76. doi: 10.1034/j.1600-0404.107.s179.10.x. Acta Neurol Scand Suppl. 2003. PMID: 12603252 Review.
-
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.Am J Psychiatry. 2002 May;159(5):738-45. doi: 10.1176/appi.ajp.159.5.738. Am J Psychiatry. 2002. PMID: 11986126
Cited by
-
DeepFDR: A Deep Learning-based False Discovery Rate Control Method for Neuroimaging Data.Proc Mach Learn Res. 2024 May;238:946-954. Proc Mach Learn Res. 2024. PMID: 38741695 Free PMC article.
-
Personalized, Precision Medicine to Cure Alzheimer's Dementia: Approach #1.Int J Mol Sci. 2024 Mar 31;25(7):3909. doi: 10.3390/ijms25073909. Int J Mol Sci. 2024. PMID: 38612719 Free PMC article. Review.
-
Alterations in cognitive function and blood biomarkers following transcranial direct current stimulation in patients with amyloid positron emission tomography-positive Alzheimer's disease: a preliminary study.Front Neurosci. 2023 Dec 21;17:1327886. doi: 10.3389/fnins.2023.1327886. eCollection 2023. Front Neurosci. 2023. PMID: 38178837 Free PMC article.
-
Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease.Alzheimers Res Ther. 2023 Oct 14;15(1):176. doi: 10.1186/s13195-023-01304-8. Alzheimers Res Ther. 2023. PMID: 37838690 Free PMC article. Review.
-
Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview.Cells. 2023 Aug 8;12(16):2019. doi: 10.3390/cells12162019. Cells. 2023. PMID: 37626828 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical